Satellos Bioscience Inc Stock Price, News & Analysis

Satellos Bioscience (OTCQB: MSCLF) announced it will present two scientific posters at the 30th Annual Congress of the World Muscle Society (WMS) in Vienna, Austria, from October 7-11, 2025. The presentations will feature new analyses from the Phase 1b study of SAT-3247, their investigational treatment for Duchenne muscular dystrophy.

The company's Chief Medical Officer, Dr. Wildon Farwell, will present late-breaking data from the Phase 1a/b study in healthy volunteers and adult Duchenne patients. Additionally, Dr. Ryan Mitchell, SVP of Medical & Scientific Affairs, will provide a clinical progress update on SAT-3247, which is designed to address deficits in muscle repair and regeneration.

Satellos Bioscience (OTCQB: MSCLF) has submitted an Investigational New Drug (IND) application to the FDA and parallel regulatory filings globally to initiate a Phase 2 clinical trial of SAT-3247 in children with Duchenne muscular dystrophy (DMD).

The three-month randomized, placebo-controlled study will evaluate safety, pharmacokinetics, and functional measures in ambulatory children, with the first patient enrollment expected by end of 2025. The company's Phase 1b study showed promising results, with patients experiencing doubled grip strength and 5% improvement in lung function.

Additionally, Satellos has initiated an 11-month extension study in Australia and received C$1.04 million through warrant exercises in Q3 2025.

Satellos Bioscience (OTCQB:MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in four major healthcare investor conferences this September.

The company will attend the Wells Fargo Healthcare Conference (Sept. 3, Boston), Cantor Fitzgerald Global Healthcare Conference (Sept. 5, New York), H.C. Wainwright Global Investment Conference (Sept. 9, New York), and Morgan Stanley Global Healthcare Conference (Sept. 10, New York). Two of these events will feature fireside chats that will be available via webcast on the company's investor relations website.

Satellos Bioscience (OTCQB: MSCLF) reported positive Phase 1b results for SAT-3247 in treating Duchenne muscular dystrophy (DMD). The trial demonstrated safety and an approximate doubling in grip strength in five adult DMD patients after 28 days of treatment.

The company plans to initiate a follow-up study in Q3 2025, with 3-month interim data expected by year-end. Satellos is also preparing for a global Phase 2 randomized trial in children with DMD, pending regulatory approvals.

Financially, Satellos ended Q2 2025 with $38.2 million in cash, reporting a net loss of $5.6 million ($0.03 per share) compared to $4.4 million ($0.04 per share) in Q2 2024. R&D expenses increased to $4.4 million from $3.6 million year-over-year.

Satellos Bioscience (OTCQB: MSCLF), a clinical-stage biotech company focused on developing treatments for degenerative muscle diseases, has announced its participation in the Canaccord Genuity's 45th Annual Growth Conference. The event will take place on August 13-14, 2025, at the InterContinental Boston.

Management will deliver a presentation on Wednesday, August 13, from 12:30 to 12:55 p.m. ET in Abigail Adams C and will be available for one-on-one meetings. Investors can access the live webcast through the Events and Presentations page in the Investors section of Satellos' website, with a replay available after the event.

Satellos Bioscience (OTCQB: MSCLF) has appointed Dr. Wildon Farwell as Chief Medical Officer to advance their muscle disease therapeutic programs. Dr. Farwell joins from Dyne Therapeutics, where he served as CMO and brings significant expertise in neuromuscular disease drug development.

Dr. Farwell's notable achievements include building Dyne's development organization and leading their DMD and DM1 programs. At Biogen, he led the development of SPINRAZA®, the first approved treatment for spinal muscular atrophy, and initiated late-stage development of QALSODY® for ALS.

In his new role, Dr. Farwell will focus on advancing SAT-3247 into a global Phase 2 clinical trial for children with Duchenne muscular dystrophy (DMD). He succeeds Dr. Jordan Dubow, who will continue as a consultant and Clinical Advisory Board chair.

[ "Appointment of highly experienced CMO with proven track record in neuromuscular disease drug development", "New CMO has successful history of regulatory approvals, including SPINRAZA®", "Progress toward Phase 2 clinical trial for SAT-3247 in DMD treatment" ]

Satellos Bioscience (MSCLF) has elected two new board members, Dr. Iris Loew-Friedrich and Dr. Selwyn Ho, bringing significant expertise in clinical development and commercial strategy. Dr. Loew-Friedrich, former EVP and CMO at UCB, led global development and regulatory strategies resulting in multiple blockbuster therapy approvals. Dr. Ho brings extensive experience in commercial strategy and business development, having held senior roles at companies like Dermira, UCB, and Allergan. As CEO of Medigene AG, he led strategic partnerships and raised over $350M through IPO and private funding. Three board members - Dr. Rima Al-awar, William Jarosz, and Dr. William McVicar - did not seek reelection. The appointments come as Satellos advances its SAT-3247 program for Duchenne muscular dystrophy treatment.

Satellos Bioscience (MSCLF) held its Annual and Special Meeting of Shareholders on June 18, 2025, with 41.15% of outstanding shares represented. All nominated directors were successfully elected with over 97% approval rates. The most notable outcome was shareholders' approval of a potential reverse stock split ranging from 1-for-5 to 1-for-15, subject to Board implementation. The exact ratio and effective date will be announced later if the Board proceeds. Shareholders also approved PricewaterhouseCoopers LLP's reappointment as auditors. The meeting demonstrated strong shareholder support for the company's leadership, with directors receiving approval rates between 97.41% and 99.99%.

Satellos Bioscience (MSCLF) announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, scheduled for June 19-21 in Las Vegas. The conference brings together families, researchers, clinicians, and companies focused on improving outcomes for Duchenne patients. Satellos, a biotech company developing small molecule therapeutics for muscle diseases, will engage with the Duchenne community and share updates on their scientific approach to regenerate muscle from within. The company will maintain a presence at the exhibition hall where attendees can meet team members and learn more about their work.